Auch wenn Corona nicht mehr das beherrschende Thema in den Medien ist, so steht die Impfung nach wie vor im Raum. Valneva SE bestätigt nun , dass in den kommenden Wochen 1,25 Millionen Dosen des [...]
Valneva SE announced that the United Arab Emirates (UAE) granted emergency use authorization for its inactivated, adjuvanted COVID-19 vaccine, VLA2001. […]
Kann der inaktivierte Ganzvirus-Impfstoffkandidat VLA2001 von Valneva als Auffrischungs-Impfung nach einer mRNA-Covid-19 Impfung verwendet werden? Diese Frage überprüft aktuell Valneva SE in einer heterologen Booster-Studie. […]
On 14th of April Valneva SE announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted Conditional Marketing Authorization (CMA) for its inactivated whole-virus COVID-19 vaccine candidate, VLA2001, for [...]
On 25th of January Valneva SE announced the start of booster vaccinations in adult participants from its Phase 3 pivotal trial, Cov-Compare. This booster extension is intended to provide both homologous and first heterologous booster [...]
Valneva SE commenced rolling submission, for initial approval of its COVID-19 vaccine candidate, VLA2001, with the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK). VLA2001 is a whole virus, inactivated, adjuvanted [...]
Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV). In areas where the virus is circulating it affects one-third to three-quarters of the population. The medical and economic burden is expected to [...]